Sentinel lymph node biopsy in operations for recurrent breast cancer

Eur J Surg Oncol. 2008 Jun;34(6):626-30. doi: 10.1016/j.ejso.2007.09.004. Epub 2007 Oct 29.

Abstract

Background: In a pilot prospective consecutive series on 50 patients with recurrent breast cancer, results of sentinel lymph node biopsy (SLNB) are reported. The interval between primary operation and recurrence was 8years (range 1-18years). Only three patients had not undergone dissection of the axilla (ALND).

Results: In 51% of patients scintigraphy disclosed sentinel nodes (SN). At operation SN was identified in 45% of patients corresponding to 83% of the SN's visualized by the scintigraphy. SN contained metastases in seven cases (16%), and the treatment plan was changed as a consequence of the SN examination.

Conclusion: SLNB can identify SN at a high rate, and the findings may influence further planning of treatment. SLNB should be a future standard procedure in operations for recurrent breast cancer. Next step should be a randomized study.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Axilla
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery
  • Female
  • Humans
  • Lymphatic Metastasis
  • Mastectomy
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Recurrence, Local / surgery
  • Pilot Projects
  • Prospective Studies
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Salvage Therapy
  • Sentinel Lymph Node Biopsy*
  • Technetium Tc 99m Aggregated Albumin

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Aggregated Albumin
  • technetium Tc 99m nanocolloid